<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3472">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01378429</url>
  </required_header>
  <id_info>
    <org_study_id>060-308</org_study_id>
    <nct_id>NCT01378429</nct_id>
  </id_info>
  <brief_title>Safety Study of the Potential Inhibitory Effects of Ciclesonide Nasal Aerosol on the Hypothalamic-Pituitary-Adrenal Axis in Subjects 6-11 Years With Perennial Allergic Rhinitis</brief_title>
  <official_title>A 6-Week Randomized, Double-blind, Placebo-controlled, Parallel Group, Safety Study of the Potential Inhibitory Effects of Ciclesonide Nasal Aerosol on the Hypothalamic-Pituitary-Adrenal (HPA) Axis in Subjects 6-11 Years With Perennial Allergic Rhinitis (PAR)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sunovion</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sunovion</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, randomized, double-blind, placebo-controlled, parallel group, safety
      study of the effects of ciclesonide nasal aerosol (74 mcg) on the HPA axis when administered
      once daily to male and premenarchal female subjects 6 to 11 years of age with a diagnosis of
      PAR.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, randomized, double-blind, placebo-controlled, parallel group, safety
      study of the effects of ciclesonide nasal aerosol (74 mcg) on the HPA axis when administered
      once daily to male and premenarchal female subjects 6 to 11 years of age with a diagnosis of
      PAR.

      The study requires that subjects be domiciled during two 24- to 36-hour time periods for
      sample collection for serum and urinary free cortisol measurements, as well as PK
      evaluations (single [predose] time point during the first domiciled period, and 24-hour
      sampling during the second domiciled period).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>The Change in Serum Cortisol Area Under the Curve (AUC) From Time 0 to 24 Hours (0-24), Calculated Using a Trapezoidal Rule, From Baseline to the End of the 6 Week Treatment Period</measure>
    <time_frame>Week 0 and 6</time_frame>
    <safety_issue>No</safety_issue>
    <description>Area under the concentration-time curve from time 0 to 24 hours [AUC(0-24h)]. Timepoints at which data were collected: 0, 2, 4, 8, 12, 16, and 24 at week 0 and 6.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Urinary Free Cortisol-Corrected for Urine Creatinine</measure>
    <time_frame>weeks 0-6</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Urinary Free Cortisol-Uncorrected for Urine Creatinine</measure>
    <time_frame>weeks 0-6</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Experiencing AEs</measure>
    <time_frame>weeks 0-6</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects Experiencing AEs</measure>
    <time_frame>weeks 0-6</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Experiencing Nasal AEs, Including Epistaxis, Nasal Ulceration, and Nasal Perforation.</measure>
    <time_frame>weeks 0-6</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Local Treatment-Emergent Adverse Events (ITT Population)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects Experiencing Nasal AEs, Including Epistaxis, Nasal Ulceration, and Nasal Perforation.</measure>
    <time_frame>weeks 0-6</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Local Treatment-Emergent Adverse Events (ITT Population)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(0-24h)</measure>
    <time_frame>Week 6</time_frame>
    <safety_issue>No</safety_issue>
    <description>Area under the concentration-time curve from time 0 to 24 hours. Collected at 0, 30 min, 60 min, 90 min, 2 hours (h), 4 h, 8 h, 12 h, 16 h, and 24h after dosing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Concentration</measure>
    <time_frame>Week 6</time_frame>
    <safety_issue>No</safety_issue>
    <description>Cmax (ng/mL) (PK Population)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to the Occurrence of Cmax</measure>
    <time_frame>Week 6</time_frame>
    <safety_issue>No</safety_issue>
    <description>tmax (hour) (PK Population)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Half Life (t1/2)</measure>
    <time_frame>Weeks 6</time_frame>
    <safety_issue>No</safety_issue>
    <description>Terminal half-life (t1/2) (hour)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Clearance of the Drug (CL/F)</measure>
    <time_frame>Week 6</time_frame>
    <safety_issue>No</safety_issue>
    <description>CL/F liter per hour (L/hour) is the apparent clearance of the drug</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Volume of Distribution (Vz/F)</measure>
    <time_frame>Week 6</time_frame>
    <safety_issue>No</safety_issue>
    <description>Vz/F Liters (L) is the apparent volume of distribution</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio (Percentage) of the Number of Correct Advances of the Dose Indicator to the Number of Expected Advances Based on Subject Self-report of Study Medication Administration Plus Extra Non-nasal Actuations</measure>
    <time_frame>weeks 0-6</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Devices With Actuation Consistency, Where Actuation Consistency is Defined as a Dose Indicator Count Within ± 20% of the Subject Self-report of Study Medication Administration</measure>
    <time_frame>weeks 0-6</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Devices With Actuation Consistency, Where Actuation Consistency is Defined as a Dose Indicator Count Within ± 20% of the Subject Self-report of Study Medication Administration</measure>
    <time_frame>weeks 0-6</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Averaged Daily Subject-reported AM and PM Reflective TNSS Averaged Over the 6 Weeks of Double-blind Treatment</measure>
    <time_frame>weeks 0-6</time_frame>
    <safety_issue>No</safety_issue>
    <description>TNSS is the sum of individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where: 0 = absent 1 = mild 2 = moderate 3 = severe Therefore, rTNSS values range from 0-12 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Reflective TNSS measures these symptoms over the previous 12-hour time interval. Difference was calculated as the six week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">89</enrollment>
  <condition>Perennial Allergic Rhinitis</condition>
  <condition>PAR</condition>
  <arm_group>
    <arm_group_label>ciclesonide nasal aerosol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ciclesonide nasal aerosol (74 mcg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ciclesonide nasal aerosol</intervention_name>
    <description>ciclesonide nasal aerosol (74 mcg)</description>
    <arm_group_label>ciclesonide nasal aerosol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Gives written informed consent (parent/legal guardian) and assent (when appropriate,
             from the child), including privacy authorization as well as adherence to concomitant
             medication withholding periods, prior to participation.

          -  Is a male or premenarchal female 6 to 11 years old and ≥ 20 kg at the screening
             visit.

          -  Is in general good health (defined as the absence of any clinically relevant
             abnormalities as determined by the investigator) based on screening physical
             examination and medical history.

          -  Has a history of PAR to a relevant perennial allergen (house dust mites, cockroaches,
             molds, animal dander) for a minimum of one year immediately preceding the study
             screening visit. The PAR must have been of sufficient severity to have required
             treatment (either continuous or intermittent) in the past and require treatment
             throughout the entire study period.

          -  Has a demonstrated sensitivity to at least one allergen known to induce PAR (house
             dust mites, cockroaches, molds, and animal dander) based on a documented result with
             a standard skin-prick test either within one year prior to the screening visit or
             performed at the screening visit. A positive test is defined as a wheal diameter at
             least 3 mm larger than the negative control wheal for the skin-prick test. The
             subject's positive allergen test must be consistent with the medical history of of
             PAR, and the allergen must be present in the subject's environment throughout the
             study.

        Exclusion Criteria:

          -  Has a history of physical findings of nasal pathology, including nasal polyps or
             other clinically significant respiratory tract malformations; recent nasal biopsy;
             nasal trauma; or nasal ulcers or perforations. Surgery and atrophic rhinitis or
             rhinitis medicamentosa are not permitted within the 120 days prior to the screening
             visit.

          -  Has evidence of infection, significant anatomic abnormality, ulceration of the
             mucosa, blood in the nose, or any other clinically relevant finding on nasal
             examination at the screening visit.

          -  Has nasal jewelry.

          -  Has participated in any investigational drug trial within the 30 days preceding the
             screening visit or is planning participation in another investigational drug trial at
             any time during this trial.

          -  Has a known hypersensitivity to any corticosteroid or any of the excipients in the
             formulation of ciclesonide.

          -  Has a history of a respiratory infection or disorder, including but not limited to
             bronchitis, pneumonia, influenza, and severe acute respiratory syndrome (SARS),
             within the 14 days preceding the screening visit.

          -  Has a history of adrenal insufficiency.

          -  Has active asthma requiring treatment with inhaled or systemic corticosteroids and/or
             routine use of beta-agonists and any controller drugs (eg, theophylline, leukotriene
             antagonists); intermittent use (≤ 3 uses per week) of inhaled short-acting
             beta-agonists is acceptable. Use of short-acting beta-agonists for exercise-induced
             bronchospasm will be allowed.

          -  Is expecting to use any disallowed concomitant medications during the treatment
             period.

          -  Is, in the investigator's judgment, having a seasonal exacerbation at the time of the
             screening visit.

          -  Is planning initiation of immunotherapy during the study period or dose escalation
             during the study period. However, initiation of immunotherapy 90 days or more prior
             to the screening visit and use of a stable (maintenance) dose (30 days or more) may
             be considered for inclusion.

          -  Has nonvaccinated exposure to or active infection with chickenpox or measles within
             the 21 days preceding the screening visit.

          -  Initiates pimecrolimus cream 1% or greater or tacrolimus ointment 0.03% or greater
             during the study period or plans a dose escalation during the study period. However,
             initiation of these creams/ointments 30 days or more prior to screening and use of a
             stable (maintenance) dose during the study period may be considered for inclusion.

          -  Has experienced significant blood loss within 60 days or loss of plasma within 72
             hours prior to the screening visit or intends to undergo elective surgery within 30
             days following end of study.

          -  Is a child or immediate relative of any clinical investigator or site personnel, even
             those who are not directly involved in this study.

          -  Resides in the same household as another subject who is participating in this study
             at the same time.

          -  Has any of the following conditions that are judged by the investigator to be
             clinically significant and/or to affect the subject's ability to participate in the
             clinical trial:

               -  impaired hepatic function

               -  history of ocular disturbances, eg, glaucoma or posterior subcapsular cataracts
                  or herpes simplex

               -  any systemic infection

               -  hematological (including anemia), hepatic, renal, endocrine disease

               -  gastrointestinal disease

               -  malignancy (excluding basal cell carcinoma)

               -  current neuropsychological condition with or without drug therapy. Any
                  behavioral condition that could affect subject's ability to accurately report
                  symptoms to the caregiver such as developmental delay, attention deficit
                  disorder, and autism.

          -  Has any condition that, in the judgment of the investigator, would preclude the
             subject from completing the protocol with capture of the assessments as written.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>11 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>West Coast Clinical Trials</name>
      <address>
        <city>Costa Mesa</city>
        <state>California</state>
        <zip>92626</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Atlanta</name>
      <address>
        <city>Stockbridge</city>
        <state>Georgia</state>
        <zip>30281</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sneeze, Wheeze, &amp; Itch Associates, LLC</name>
      <address>
        <city>Normal</city>
        <state>Illinois</state>
        <zip>61761</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Institute</name>
      <address>
        <city>Plymouth</city>
        <state>Minnesota</state>
        <zip>55441</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western Sky Medical Research</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Texas Health Research</name>
      <address>
        <city>New Braunfels</city>
        <state>Texas</state>
        <zip>78130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sylvania Research Associates</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 29, 2014</lastchanged_date>
  <firstreceived_date>June 20, 2011</firstreceived_date>
  <firstreceived_results_date>December 19, 2013</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Perennial Allergic Rhinitis</keyword>
  <keyword>PAR</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic, Perennial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ciclesonide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Placebo: Placebo</description>
        </group>
        <group group_id="P2">
          <title>Ciclesonide Nasal Aerosol</title>
          <description>ciclesonide nasal aerosol (74 mcg)
ciclesonide nasal aerosol: ciclesonide nasal aerosol (74 mcg)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
                <participants group_id="P2" count="47"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="47"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Noncompliance with study drug</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Placebo nasal aerosol administered once daily (1 actuation per nostril)</description>
        </group>
        <group group_id="B2">
          <title>Ciclesonide Nasal Aerosol (74 mcg)</title>
          <description>Ciclesonide nasal aerosol 74 mcg administered once daily (1 actuation of 37 mcg per nostril)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="42"/>
                <measurement group_id="B2" value="47"/>
                <measurement group_id="B3" value="89"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="9.2" spread="1.74"/>
                <measurement group_id="B2" value="8.6" spread="1.65"/>
                <measurement group_id="B3" value="8.9" spread="1.70"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="42"/>
                <measurement group_id="B2" value="47"/>
                <measurement group_id="B3" value="89"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="22"/>
                <measurement group_id="B2" value="22"/>
                <measurement group_id="B3" value="44"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="20"/>
                <measurement group_id="B2" value="25"/>
                <measurement group_id="B3" value="45"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>American Indian or Alaska Native</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Asian</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="2"/>
                <measurement group_id="B2" value="2"/>
                <measurement group_id="B3" value="4"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Native Hawaiian or Other Pacific Islander</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Black or African American</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="11"/>
                <measurement group_id="B2" value="8"/>
                <measurement group_id="B3" value="19"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>White</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="29"/>
                <measurement group_id="B2" value="35"/>
                <measurement group_id="B3" value="64"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>More than one race</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="2"/>
                <measurement group_id="B3" value="2"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Unknown or Not Reported</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Hispanic or Latino</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="15"/>
                <measurement group_id="B2" value="17"/>
                <measurement group_id="B3" value="32"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Not Hispanic or Latino</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="27"/>
                <measurement group_id="B2" value="30"/>
                <measurement group_id="B3" value="57"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Unknown or Not Reported</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="42"/>
                <measurement group_id="B2" value="47"/>
                <measurement group_id="B3" value="89"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Change in Serum Cortisol Area Under the Curve (AUC) From Time 0 to 24 Hours (0-24), Calculated Using a Trapezoidal Rule, From Baseline to the End of the 6 Week Treatment Period</title>
        <description>Area under the concentration-time curve from time 0 to 24 hours [AUC(0-24h)]. Timepoints at which data were collected: 0, 2, 4, 8, 12, 16, and 24 at week 0 and 6.</description>
        <time_frame>Week 0 and 6</time_frame>
        <safety_issue>No</safety_issue>
        <population>The Per Protocol (PP) population consisted of all ITT subjects who had sufficient blood sample collection at Visit 4/BL and Visit 7/End of Week 6 for serum cortisol measurements, completed the study on treatment medication and had no important protocol deviations (IPDs).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo nasal aerosol administered once daily (1 actuation per nostril)</description>
          </group>
          <group group_id="O2">
            <title>Ciclesonide Nasal Aerosol</title>
            <description>Ciclesonide nasal aerosol 74 mcg administered once daily (1 actuation of 37 mcg per nostril)</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="39"/>
                  <measurement group_id="O2" value="46"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>The Change in Serum Cortisol Area Under the Curve (AUC) From Time 0 to 24 Hours (0-24), Calculated Using a Trapezoidal Rule, From Baseline to the End of the 6 Week Treatment Period</title>
            <description>Area under the concentration-time curve from time 0 to 24 hours [AUC(0-24h)]. Timepoints at which data were collected: 0, 2, 4, 8, 12, 16, and 24 at week 0 and 6.</description>
            <units>mcg•hour/dL</units>
            <param>Least Squares Mean</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="5.9" spread="5.6"/>
                  <measurement group_id="O2" value="-1.7" spread="5.2"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>35 subjects per arm would have ≥90% power to demonstrate that the upper bound of a two-sided 95% confidence interval (equivalent to the upper bound of a one-sided 97.5% confidence interval) of the difference of placebo minus ciclesonide nasal aerosol would be less than 20% of the baseline value of 175 mcg•h/dL or a noninferiority limit of 35 mcg•h/dL assuming a SD of 40 and a one-sided α of 0.025. A total of 40 subjects will be randomly assigned to ensure 35 subjects complete the study per arm.</groups_desc>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>35 subjects per arm would have ≥90% power to demonstrate that the upper bound of a two-sided 95% confidence interval (equivalent to the upper bound of a one-sided 97.5% confidence interval) of the difference of placebo minus ciclesonide nasal aerosol would be less than 20% of the baseline value of 175 mcg•h/dL or a noninferiority limit of 35 mcg•h/dL assuming a SD of 40 and a one-sided α of 0.025. A total of 40 subjects will be randomly assigned to ensure 35 subjects complete the study per arm.</non_inferiority_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>7.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.4</ci_lower_limit>
            <ci_upper_limit>22.6</ci_upper_limit>
            <estimate_desc>Difference is calculated as Placebo - Ciclesonide.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Urinary Free Cortisol-Corrected for Urine Creatinine</title>
        <time_frame>weeks 0-6</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>The PP population. Subjects with either missing baseline data or post dose data, or both were not included in the analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo nasal aerosol administered once daily (1 actuation per nostril)</description>
          </group>
          <group group_id="O2">
            <title>Ciclesonide Nasal Aerosol</title>
            <description>Ciclesonide nasal aerosol 74 mcg administered once daily (1 actuation of 37 mcg per nostril)</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="39"/>
                  <measurement group_id="O2" value="45"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change From Baseline in Urinary Free Cortisol-Corrected for Urine Creatinine</title>
            <units>mcg/g</units>
            <param>Least Squares Mean</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1.4" spread="2.9"/>
                  <measurement group_id="O2" value="3.3" spread="2.7"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Urinary Free Cortisol-Uncorrected for Urine Creatinine</title>
        <time_frame>weeks 0-6</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>The PP population consisted of all ITT subjects who had sufficient blood sample collection at Visit 4/BL and Visit 7/End of Week 6 for serum cortisol measurements, completed the study on treatment medication and had no IPDs.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo nasal aerosol administered once daily (1 actuation per nostril) for 6 weeks</description>
          </group>
          <group group_id="O2">
            <title>Ciclesonide Nasal Aerosol</title>
            <description>Ciclesonide nasal aerosol 74 mcg administered once daily (1 actuation of 37 mcg per nostril) for 6 weeks</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="39"/>
                  <measurement group_id="O2" value="45"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change From Baseline in Urinary Free Cortisol-Uncorrected for Urine Creatinine</title>
            <units>mcg/g</units>
            <param>Least Squares Mean</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0.5" spread="1.9"/>
                  <measurement group_id="O2" value="1.2" spread="1.8"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Experiencing AEs</title>
        <time_frame>weeks 0-6</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>Intent-to-treat (ITT) Population: All randomized subjects who received at least 1 dose of double blind study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo nasal aerosol administered once daily (1 actuation per nostril)</description>
          </group>
          <group group_id="O2">
            <title>Ciclesonide Nasal Aerosol</title>
            <description>Ciclesonide nasal aerosol 74 mcg administered once daily (1 actuation of 37 mcg per nostril)</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="42"/>
                  <measurement group_id="O2" value="47"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Experiencing AEs</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Any AE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="19"/>
                  <measurement group_id="O2" value="20"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Potentially related AE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                  <measurement group_id="O2" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Nasal (local) AEs</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                  <measurement group_id="O2" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Discontinued study drug due to an AE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Severe AE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Serious AE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Death</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects Experiencing AEs</title>
        <time_frame>weeks 0-6</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>Intent-to-treat (ITT) Population: All randomized subjects who received at least 1 dose of double blind study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo nasal aerosol administered once daily (1 actuation per nostril)</description>
          </group>
          <group group_id="O2">
            <title>Ciclesonide Nasal Aerosol</title>
            <description>Ciclesonide nasal aerosol 74 mcg administered once daily (1 actuation of 37 mcg per nostril)</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="42"/>
                  <measurement group_id="O2" value="47"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percentage of Subjects Experiencing AEs</title>
            <units>percentage of participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Any AE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="45.2"/>
                  <measurement group_id="O2" value="42.6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Potentially related AE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="14.3"/>
                  <measurement group_id="O2" value="8.5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Nasal (local) AEs</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="14.3"/>
                  <measurement group_id="O2" value="10.6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Discontinued study drug due to an AE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Severe AE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.4"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Serious AE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Death</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Experiencing Nasal AEs, Including Epistaxis, Nasal Ulceration, and Nasal Perforation.</title>
        <description>Local Treatment-Emergent Adverse Events (ITT Population)</description>
        <time_frame>weeks 0-6</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>Intent-to-treat (ITT) Population: All randomized subjects who received at least 1 dose of double blind study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo nasal aerosol administered once daily (1 actuation per nostril)</description>
          </group>
          <group group_id="O2">
            <title>Ciclesonide Nasal Aerosol</title>
            <description>Ciclesonide nasal aerosol 74 mcg administered once daily (1 actuation of 37 mcg per nostril)</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="42"/>
                  <measurement group_id="O2" value="47"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Experiencing Nasal AEs, Including Epistaxis, Nasal Ulceration, and Nasal Perforation.</title>
            <description>Local Treatment-Emergent Adverse Events (ITT Population)</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Overall</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                  <measurement group_id="O2" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Epistaxis</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Mucosal erosion</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Nasal discomfort</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Postnasal drip</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Rhinitis</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Rhinorrhea</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Traumatic hemorrhage</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Upper respiratory tract infection</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects Experiencing Nasal AEs, Including Epistaxis, Nasal Ulceration, and Nasal Perforation.</title>
        <description>Local Treatment-Emergent Adverse Events (ITT Population)</description>
        <time_frame>weeks 0-6</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>Intent-to-treat (ITT) Population: All randomized subjects who received at least 1 dose of double blind study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo nasal aerosol administered once daily (1 actuation per nostril) for 6 weeks</description>
          </group>
          <group group_id="O2">
            <title>Ciclesonide Nasal Aerosol</title>
            <description>Ciclesonide nasal aerosol 74 mcg administered once daily (1 actuation of 37 mcg per nostril) for 6 weeks</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="42"/>
                  <measurement group_id="O2" value="47"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percentage of Subjects Experiencing Nasal AEs, Including Epistaxis, Nasal Ulceration, and Nasal Perforation.</title>
            <description>Local Treatment-Emergent Adverse Events (ITT Population)</description>
            <units>percentage of participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Overall</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="14.3"/>
                  <measurement group_id="O2" value="10.6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Epistaxis</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4.8"/>
                  <measurement group_id="O2" value="2.1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Mucosal erosion</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.4"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Nasal discomfort</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.4"/>
                  <measurement group_id="O2" value="2.1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Postnasal drip</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="2.1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Rhinitis</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.4"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Rhinorrhea</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="2.1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Traumatic hemorrhage</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.4"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Upper respiratory tract infection</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="2.1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4.8"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC(0-24h)</title>
        <description>Area under the concentration-time curve from time 0 to 24 hours. Collected at 0, 30 min, 60 min, 90 min, 2 hours (h), 4 h, 8 h, 12 h, 16 h, and 24h after dosing.</description>
        <time_frame>Week 6</time_frame>
        <safety_issue>No</safety_issue>
        <population>PK Population: Subjects in the ITT population who completed the study on treatment medication and had assayed serum concentrations of ciclesonide and/or des ciclesonide. Descriptive statistics were presented for serum drug/metabolite concentrations and evaluable pharmacokinetic parameters.</population>
        <group_list>
          <group group_id="O1">
            <title>Ciclesonide Nasal Aerosol</title>
            <description>Ciclesonide nasal aerosol 74 mcg administered once daily (1 actuation of 37 mcg per nostril)</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="47"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>AUC(0-24h)</title>
            <description>Area under the concentration-time curve from time 0 to 24 hours. Collected at 0, 30 min, 60 min, 90 min, 2 hours (h), 4 h, 8 h, 12 h, 16 h, and 24h after dosing.</description>
            <units>ng*hr/mL</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Ciclesonide serum concentration</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.072" spread="0.261"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Des-ciclesonide serum concentration</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.261" spread="0.139"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Observed Concentration</title>
        <description>Cmax (ng/mL) (PK Population)</description>
        <time_frame>Week 6</time_frame>
        <safety_issue>No</safety_issue>
        <population>PK Population: Subjects in the ITT population who completed the study on treatment medication and had assayed serum concentrations of ciclesonide and/or des ciclesonide. Descriptive statistics were presented for serum drug/metabolite concentrations and evaluable pharmacokinetic parameters.</population>
        <group_list>
          <group group_id="O1">
            <title>Ciclesonide Nasal Aerosol</title>
            <description>Ciclesonide nasal aerosol 74 mcg administered once daily (1 actuation of 37 mcg per nostril)</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="47"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Maximum Observed Concentration</title>
            <description>Cmax (ng/mL) (PK Population)</description>
            <units>ng/mL</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Ciclesonide serum concentration</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.012" spread="0.0009"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Des-ciclesonide serum concentration</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.029" spread="0.0169"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to the Occurrence of Cmax</title>
        <description>tmax (hour) (PK Population)</description>
        <time_frame>Week 6</time_frame>
        <safety_issue>No</safety_issue>
        <population>PK Population: Subjects in the ITT population who completed the study on treatment medication and had assayed serum concentrations of ciclesonide and/or des ciclesonide. Descriptive statistics were presented for serum drug/metabolite concentrations and evaluable pharmacokinetic parameters.</population>
        <group_list>
          <group group_id="O1">
            <title>Ciclesonide Nasal Aerosol</title>
            <description>Ciclesonide nasal aerosol 74 mcg administered once daily (1 actuation of 37 mcg per nostril)</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="47"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Time to the Occurrence of Cmax</title>
            <description>tmax (hour) (PK Population)</description>
            <units>Hour</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Ciclesonide serum concentration</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.146" spread="0.700"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Des-ciclesonide serum concentration</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.200" spread="1.330"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Terminal Half Life (t1/2)</title>
        <description>Terminal half-life (t1/2) (hour)</description>
        <time_frame>Weeks 6</time_frame>
        <safety_issue>No</safety_issue>
        <population>PK Population: Subjects in the ITT population who completed the study on treatment medication and had assayed serum concentrations of ciclesonide and/or des ciclesonide. Descriptive statistics were presented for serum drug/metabolite concentrations and evaluable pharmacokinetic parameters.</population>
        <group_list>
          <group group_id="O1">
            <title>Ciclesonide Nasal Aerosol</title>
            <description>Ciclesonide nasal aerosol 74 mcg administered once daily (1 actuation of 37 mcg per nostril)</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="47"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Terminal Half Life (t1/2)</title>
            <description>Terminal half-life (t1/2) (hour)</description>
            <units>Hour</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Ciclesonide serum concentration</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8.194" spread="12.448"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Des-ciclesonide serum concentration</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="11.727" spread="5.864"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Clearance of the Drug (CL/F)</title>
        <description>CL/F liter per hour (L/hour) is the apparent clearance of the drug</description>
        <time_frame>Week 6</time_frame>
        <safety_issue>No</safety_issue>
        <population>PK Population: Subjects in the ITT population who completed the study on treatment medication and had assayed serum concentrations of ciclesonide and/or des ciclesonide. Descriptive statistics were presented for serum drug/metabolite concentrations and evaluable pharmacokinetic parameters.</population>
        <group_list>
          <group group_id="O1">
            <title>Ciclesonide Nasal Aerosol</title>
            <description>Ciclesonide nasal aerosol 74 mcg administered once daily (1 actuation of 37 mcg per nostril)</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="47"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Apparent Clearance of the Drug (CL/F)</title>
            <description>CL/F liter per hour (L/hour) is the apparent clearance of the drug</description>
            <units>L/hour</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Ciclesonide serum concentration</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1222.4" spread="573.99"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Des-ciclesonide serum concentration</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="317.8" spread="190.49"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Volume of Distribution (Vz/F)</title>
        <description>Vz/F Liters (L) is the apparent volume of distribution</description>
        <time_frame>Week 6</time_frame>
        <safety_issue>No</safety_issue>
        <population>PK Population: Subjects in the ITT population who completed the study on treatment medication and had assayed serum concentrations of ciclesonide and/or des ciclesonide. Descriptive statistics were presented for serum drug/metabolite concentrations and evaluable pharmacokinetic parameters.</population>
        <group_list>
          <group group_id="O1">
            <title>Ciclesonide Nasal Aerosol</title>
            <description>Ciclesonide nasal aerosol 74 mcg administered once daily (1 actuation of 37 mcg per nostril)</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="47"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Apparent Volume of Distribution (Vz/F)</title>
            <description>Vz/F Liters (L) is the apparent volume of distribution</description>
            <units>L</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Ciclesonide serum concentration</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="34831.4" spread="35986.86"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Des-ciclesonide serum concentration</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6151.3" spread="7999.78"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ratio (Percentage) of the Number of Correct Advances of the Dose Indicator to the Number of Expected Advances Based on Subject Self-report of Study Medication Administration Plus Extra Non-nasal Actuations</title>
        <time_frame>weeks 0-6</time_frame>
        <safety_issue>No</safety_issue>
        <population>Intent-to-treat (ITT) Population: All randomized subjects who received at least 1 dose of double blind study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo nasal aerosol administered once daily (1 actuation per nostril)</description>
          </group>
          <group group_id="O2">
            <title>Ciclesonide Nasal Aerosol</title>
            <description>Ciclesonide nasal aerosol 74 mcg administered once daily (1 actuation of 37 mcg per nostril)</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="42"/>
                  <measurement group_id="O2" value="47"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Ratio (Percentage) of the Number of Correct Advances of the Dose Indicator to the Number of Expected Advances Based on Subject Self-report of Study Medication Administration Plus Extra Non-nasal Actuations</title>
            <units>percentage of number of correct advances</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="101.75" spread="9.647"/>
                  <measurement group_id="O2" value="100.73" spread="11.637"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Devices With Actuation Consistency, Where Actuation Consistency is Defined as a Dose Indicator Count Within ± 20% of the Subject Self-report of Study Medication Administration</title>
        <time_frame>weeks 0-6</time_frame>
        <safety_issue>No</safety_issue>
        <population>Intent-to-treat (ITT) Population: All randomized subjects who received at least 1 dose of double blind study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo nasal aerosol administered once daily (1 actuation per nostril)</description>
          </group>
          <group group_id="O2">
            <title>Ciclesonide Nasal Aerosol</title>
            <description>Ciclesonide nasal aerosol 74 mcg administered once daily (1 actuation of 37 mcg per nostril)</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="42"/>
                  <measurement group_id="O2" value="47"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Devices analyzed</title>
            <units>Devices</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="123"/>
                  <measurement group_id="O2" value="141"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Devices With Actuation Consistency, Where Actuation Consistency is Defined as a Dose Indicator Count Within ± 20% of the Subject Self-report of Study Medication Administration</title>
            <units>Devices</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="112"/>
                  <measurement group_id="O2" value="126"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Devices With Actuation Consistency, Where Actuation Consistency is Defined as a Dose Indicator Count Within ± 20% of the Subject Self-report of Study Medication Administration</title>
        <time_frame>weeks 0-6</time_frame>
        <safety_issue>No</safety_issue>
        <population>Intent-to-treat (ITT) Population: All randomized subjects who received at least 1 dose of double blind study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo nasal aerosol administered once daily (1 actuation per nostril) for 6 weeks</description>
          </group>
          <group group_id="O2">
            <title>Ciclesonide Nasal Aerosol</title>
            <description>Ciclesonide nasal aerosol 74 mcg administered once daily (1 actuation of 37 mcg per nostril) for 6 weeks</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="42"/>
                  <measurement group_id="O2" value="47"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Devices analyzed</title>
            <units>Devices</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="123"/>
                  <measurement group_id="O2" value="141"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percentage of Devices With Actuation Consistency, Where Actuation Consistency is Defined as a Dose Indicator Count Within ± 20% of the Subject Self-report of Study Medication Administration</title>
            <units>percentage of devices</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="91.1"/>
                  <measurement group_id="O2" value="89.4"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Averaged Daily Subject-reported AM and PM Reflective TNSS Averaged Over the 6 Weeks of Double-blind Treatment</title>
        <description>TNSS is the sum of individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where: 0 = absent 1 = mild 2 = moderate 3 = severe Therefore, rTNSS values range from 0-12 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Reflective TNSS measures these symptoms over the previous 12-hour time interval. Difference was calculated as the six week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement</description>
        <time_frame>weeks 0-6</time_frame>
        <safety_issue>No</safety_issue>
        <population>Intent-to-treat (ITT) Population: All randomized subjects who received at least 1 dose of double blind study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo nasal aerosol administered once daily (1 actuation per nostril)</description>
          </group>
          <group group_id="O2">
            <title>Ciclesonide Nasal Aerosol</title>
            <description>Ciclesonide nasal aerosol 74 mcg administered once daily (1 actuation of 37 mcg per nostril)</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="42"/>
                  <measurement group_id="O2" value="47"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change From Baseline in Averaged Daily Subject-reported AM and PM Reflective TNSS Averaged Over the 6 Weeks of Double-blind Treatment</title>
            <description>TNSS is the sum of individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where: 0 = absent 1 = mild 2 = moderate 3 = severe Therefore, rTNSS values range from 0-12 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Reflective TNSS measures these symptoms over the previous 12-hour time interval. Difference was calculated as the six week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement</description>
            <units>units on a scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-0.7" spread="1.65"/>
                  <measurement group_id="O2" value="-1.5" spread="2.04"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>0-6 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo: Placebo</description>
        </group>
        <group group_id="E2">
          <title>Ciclesonide Nasal Aerosol</title>
          <description>ciclesonide nasal aerosol (74 mcg)
ciclesonide nasal aerosol: ciclesonide nasal aerosol (74 mcg)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>In the event the Study is part of a multi-center study, the first publication of the results of the Study shall be made in conjunction with the results of other participating study sites as a multi-center publication; provided however, if a multi-center publication is not forthcoming within twenty-four (24) months following completion of the Study at all sites, Institution and Investigator shall be free to publish.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Respiratory Medical Director</name_or_title>
      <organization>Sunovion</organization>
      <phone>866-503-6351</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>
